कंपनी का अवलोकन
Corcept Therapeutics Incorporated operates as a biopharmaceutical entity dedicated to the discovery and development of therapeutic medications for severe endocrinologic, oncologic, metabolic, and neurologic disorders within the United States. The company functions within the Healthcare sector and specifically the Biotechnology industry, which implies a focus on high-risk, high-reward research and development cycles aimed at bringing novel treatments to market. As of the latest reporting period, the organization maintains a market capitalization of $4.49B and generates annual revenue of $761.41M, employing a workforce of 730 individuals. These financial figures indicate that Corcept holds a significant position within its niche, possessing substantial capital reserves relative to its operational scale while maintaining a robust revenue stream derived from its proprietary product portfolio, most notably Korlym.
वित्तीय स्वास्थ्य
The company reported revenue of $761.41M over the trailing twelve months, with a net income of $98.17M and EBITDA standing at $45.95M, revealing a distinct gap where operating expenses, likely driven by research and development costs, significantly compress net income below EBITDA levels. The firm generated free cash flow of $114.19M, which signifies strong financial flexibility to fund ongoing R&D initiatives, manage working capital, or pursue strategic acquisitions without immediate reliance on external financing. Profitability analysis shows a gross margin of 98.3%, indicating highly efficient production and pricing power, while the operating margin stands at 2.2% and the profit margin is 13.1%, suggesting that operating expenses constitute a major portion of gross profits before reaching the final bottom line. The balance sheet demonstrates a conservative structure with $372.15M in cash against only $6.11M in debt, supported by a debt-to-equity ratio of 0.94 which implies manageable leverage relative to shareholder equity. Liquidity is robust as evidenced by a current ratio of 2.92, indicating the company possesses nearly three times the current assets necessary to cover its short-term liabilities. Return on Equity is 15.0% while Return on Assets is 3.3%, revealing that management is generating efficient returns on shareholder capital, though the lower ROA reflects the capital-intensive nature of the biotechnology sector where asset bases are large relative to earnings.
मूल्यांकन आकलन
Valuation metrics present a trailing P/E ratio of 51.52 and a forward P/E of 26.27, where the substantial difference between these two figures implies that the market expects a significant recovery or improvement in earnings trajectory over the coming fiscal year. The price-to-book ratio is recorded at 6.91, indicating that the market values the company at nearly seven times its book value, reflecting a premium assigned to its intangible assets and intellectual property rather than tangible book value. Alternative valuation measures include a price-to-sales ratio of 5.90 and an EV/EBITDA of 89.85, which suggest that the stock is priced on high future growth expectations and revenue scalability rather than current earnings power. Regarding price momentum, the 52-week high is $91.00 and the 52-week low is $28.66, placing the current trading environment within a wide historical range that highlights significant volatility over the past year. The stock exhibits a beta of 0.25, which indicates that the share price is less volatile than the broader market, suggesting lower systematic risk relative to large-cap equities despite the inherent risks of the biotechnology sector.
Growth & Income
Revenue growth year-over-year stands at 11.1%, while earnings growth is -21.6%, indicating that earnings are growing slower than revenue, which implies that recent profitability has been under pressure despite top-line expansion. As a non-dividend payer, the company reports a dividend yield of N/A and a payout ratio of 0.0%, explaining that the organization retains all earnings to reinvest directly into research, development, and commercialization efforts rather than distributing cash to shareholders. This strategy prioritizes long-term product pipeline expansion and market penetration over immediate income generation for investors. The overall growth and income profile is characterized by double-digit revenue expansion and zero dividend distribution, creating a capital appreciation-focused investment case driven entirely by potential future earnings recovery and product adoption.